- Home
- CERO vs CYCC Comparison
CERO vs CYCC Comparison
Compare CERO & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- CYCC
- Stock Information
- Founded
- CERO 2017
- CYCC 1992
- Country
- CERO United States
- CYCC Malaysia
- Employees
- CERO N/A
- CYCC N/A
- Industry
- CERO
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- CYCC Health Care
- Exchange
- CERO Nasdaq
- CYCC Nasdaq
- Market Cap
- CERO 9.6M
- CYCC 7.8M
- IPO Year
- CERO N/A
- CYCC N/A
- Fundamental
- Price
- CERO $8.25
- CYCC $7.99
- Analyst Decision
- CERO Strong Buy
- CYCC
- Analyst Count
- CERO 2
- CYCC 0
- Target Price
- CERO $45.00
- CYCC N/A
- AVG Volume (30 Days)
- CERO 40.2K
- CYCC 227.4K
- Earning Date
- CERO 08-29-2025
- CYCC 08-13-2025
- Dividend Yield
- CERO N/A
- CYCC N/A
- EPS Growth
- CERO N/A
- CYCC N/A
- EPS
- CERO N/A
- CYCC N/A
- Revenue
- CERO N/A
- CYCC $10,000.00
- Revenue This Year
- CERO N/A
- CYCC $137.21
- Revenue Next Year
- CERO N/A
- CYCC N/A
- P/E Ratio
- CERO N/A
- CYCC N/A
- Revenue Growth
- CERO N/A
- CYCC N/A
- 52 Week Low
- CERO $6.71
- CYCC $3.08
- 52 Week High
- CERO $895.40
- CYCC $597.60
- Technical
- Relative Strength Index (RSI)
- CERO 49.24
- CYCC 44.20
- Support Level
- CERO $8.07
- CYCC $6.91
- Resistance Level
- CERO $8.90
- CYCC $8.28
- Average True Range (ATR)
- CERO 0.40
- CYCC 1.09
- MACD
- CERO 0.11
- CYCC -0.12
- Stochastic Oscillator
- CERO 59.38
- CYCC 29.43
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.